Holen Sie sich die Stockscreener-App
0.3256
9.57%
-0.0344
Handel nachbörslich:
.33
0.00445
+1.37%
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView
Summit Therapeutics Announces Proposed Public Offering of Common Stock - FinancialContent
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted - Stock Titan
Madison Avenue entities (INDV) disclose 4.32M-share, ~3.5% stake - Stock Titan
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - PharmiWeb.com
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering - BioSpace
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
Kailera Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Visa Inc. $V is Douglas Lane & Associates LLC’s 10th Largest Position - Defense World
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Stock List: Research Stocks from Around the World - GuruFocus
Terrestrial Bio to Lease Manufacturing Space at Allston Labworks - The Harvard Crimson
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire
ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
0.74%
1.44%
Kapitalisierung:
|
Volumen (24h):